Table 3 Four-year rates for DFS, DDFS, and OS in subgroups by biological subtype.

From: Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy

 

HER2-/HR + 

TNBC

HER2 + /HR + 

HER2 + /HR-

Subgroups

DFS rate (95% CI)

DDFS rate (95% CI)

OS rate (95% CI)

DFS rate (95% CI)

DDFS rate (95% CI)

OS rate (95% CI)

DFS rate (95% CI)

DDFS rate (95% CI)

OS rate (95% CI)

DFS rate (95% CI)

DDFS rate (95% CI)

OS rate (95% CI)

cT1

92.7%

(83.4%, 96.9%)

95.6%

(86.9%, 98.6%)

98.6%

(90.4%, 99.8%)

87.8%

(81.7%, 92.0%)

91.1%

(85.6%, 94.5%)

93.8%

(88.8%, 96.6%)

92.3%

(84.6%, 96.3%)

94.5%

(87.2%, 97.7%)

96.7%

(90.3%, 98.9%)

97.0%

(88.4%, 99.2%)

98.5%

(89.6%, 99.8%)

98.4%

(89.4%, 99.8%)

cT2

91.6%

(87.3%, 94.5%)

94.6%

(90.9%, 96.8%)

97.1%

(94.0%, 98.6%)

91.3%

(88.4%, 93.6%)

94.2%

(91.6%, 96.0%)

95.6%

(93.3%, 97.2%)

88.5%

(83.1%, 92.2%)

91.5%

(86.7%, 94.7%)

96.8%

(92.9%, 98.5%)

89.7%

(84.2%, 93.4%)

93.2%

(88.4%, 96.1%)

96.6%

(92.5%, 98.4%)

cT3/4

92.1%

(82.0%, 96.6%)

93.8%

(84.3%, 97.6%)

95.3%

(86.0%, 98.4%)

88.7%

(80.6%, 93.6%)

89.7%

(81.6%, 94.3%)

90.6%

(82.7%, 95.0%)

85.8%

(75.2%, 92.1%)

87.2%

(76.8%, 93.1%)

96.9%

(88.0%, 99.2%)

79.3%

(70.2%, 85.9%)

83.2%

(74.5%, 89.1%)

87.6%

(79.6%, 92.6%)

cN0

93.9%

(89.5%, 96.5%)

95.9%

(92.0%, 97.9%)

99.0%

(96.0%, 99.7%)

93.3%

(90.4%, 95.3%)

96.1%

(93.8%, 97.6%)

96.7%

(94.6%, 98.1%)

92.9%

(88.2%, 95.7%)

96.1%

(92.3%, 98.0%)

97.5%

(94.2%, 99.0%)

88.4%

(82.2%, 92.6%)

91.0%

(85.2%, 94.6%)

95.6%

(91.1%, 97.9%)

cN+

89.5%

(83.8%, 93.3%)

93.1%

(88.1%, 96.0%)

94.7%

(90.1%, 97.2%)

85.6%

(81.0%, 89.2%)

88.0%

(83.6%, 91.3%)

91.5%

(87.5%, 94.2%)

84.5%

(77.9%, 89.3%)

86.1%

(79.6%, 90.7%)

95.7%

(90.7%, 98.1%)

87.4%

(81.8%, 91.4%)

91.3%

(86.3%, 94.5%)

93.0%

(88.3%, 95.9%)

Lobular tumor type

83.6%

(64.9%, 92.8%)

87.1%

(69.1%, 94.9%)

93.5%

(76.5%, 98.3%)

70.1%

(42.3%, 86.3%)

82.4%

(54.7%, 93.9%)

82.4%

(54.7%, 93.9%)

100%

(100%,

100%)

100%

(100%,

100%)

100%

(100%,

100%)

87.5%

(38.7%, 98.1%)

87.5%

(38.7%, 98.1%)

87.5%

(38.7%, 98.1%)

Non-lobular tumor type

92.7%

(89.3%, 95.0%)

95.3%

(92.5%, 97.1%)

97.3%

(94.9%, 98.6%)

90.7%

(88.3%, 92.6%)

93.1%

(91.0%, 94.8%)

94.8%

(92.9%, 96.3%)

88.8%

(85.0%, 91.6%)

91.3%

(87.8%, 93.8%)

96.7%

(94.1%, 98.2%)

87.9%

(83.9%, 91.0%)

91.2%

(87.7%, 93.8%)

94.4%

(91.3%, 96.4%)

Ki-67 ≤ 20%

92.0%

(80.0%, 96.9%)

96.0%

(84.9%, 99.0%)

98.0%

(86.6%, 99.7%)

90.9%

(68.1%, 97.7%)

90.9%

(68.1%, 97.7%)

96.0%

(74.8%, 99.4%)

87.8%

(78.4%, 93.3%)

89.4%

(80.5%, 94.3%)

97.6%

(90.8%, 99.4%)

90.5%

(80.0%, 95.6%)

92.2%

(82.1%, 96.7%)

94.0%

(84.7%, 97.7%)

Ki-67 > 20%

91.3%

(85.5%, 94.9%)

92.0%

(86.3%, 95.4%)

95.1%

(89.9%, 97.6%)

90.3%

(86.9%, 92.8%)

93.8%

(90.9%, 95.8%)

95.7%

(93.1%, 97.3%)

90.8%

(85.8%, 94.1%)

94.4%

(90.0%, 96.8%)

97.4%

(93.8%, 98.9%)

86.7%

(80.6%, 91.0%)

90.3%

(84.8%, 93.8%)

93.6%

(88.8%, 96.4%)

Grade 1/2

90.8%

(85.6%, 94.2%)

94.1%

(89.6%, 96.7%)

97.3%

(93.7%, 98.9%)

87.1%

(80.9%, 91.4%)

89.7%

(83.9%, 93.5%)

92.5%

(87.1%, 95.7%)

87.0%

(81.3%, 91.1%)

89.6%

(84.2%, 93.3%)

96.5%

(92.4%, 98.4%)

87.0%

(80.1%, 91.6%)

90.6%

(84.3%, 94.4%)

94.1%

(88.5%, 97.0%)

Grade 3

93.2%

(88.4%, 96.1%)

94.9%

(90.4%, 97.3%)

96.5%

(92.3%, 98.4%)

91.2%

(88.5%, 93.3%)

93.8%

(91.4%, 95.5%)

95.1%

(92.9%, 96.7%)

90.5%

(85.0%, 94.1%)

93.0%

(88.0%, 96.0%)

97.0%

(92.8%, 98.7%)

88.4%

(83.2%, 92.1%)

91.4%

(86.7%, 94.5%)

94.3%

(90.1%, 96.7%)

Age ≤ 40 years

94.6%

(87.6%, 97.7%)

96.7%

(90.2%, 98.9%)

98.9%

(92.7%, 99.8%)

90.1%

(84.9%, 93.6%)

92.8%

(88.2%, 95.7%)

94.8%

(90.6%, 97.2%)

91.0%

(80.9%, 95.9%)

95.4%

(86.3%, 98.5%)

98.2%

(87.8%, 99.7%)

88.3%

(77.0%, 94.3%)

93.2%

(82.9%, 97.4%)

94.9%

(84.9%, 98.3%)

Age 41–59 years

89.9%

(85.1%, 93.1%)

93.1%

(88.9%, 95.7%)

96.0%

(92.5%, 97.9%)

90.8%

(87.6%, 93.1%)

93.1%

(90.2%, 95.1%)

94.6%

(92.0%, 96.4%)

88.0%

(83.0%, 91.6%)

90.7%

(86.1%, 93.9%)

97.2%

(93.9%, 98.8%)

86.9%

(81.5%, 90.7%)

90.8%

(86.0%, 93.9%)

94.3%

(90.2%, 96.7%)

Age ≥ 60 years

96.1%

(85.2%, 99.0%)

98.0%

(86.9%, 99.7%)

98.0%

(86.9%, 99.7%)

88.4%

(80.4%, 93.2%)

92.3%

(85.1%, 96.1%)

94.1%

(87.2%, 97.3%)

89.8%

(79.6%, 95.0%)

89.8%

(79.6%, 95.0%)

94.0%

(84.7%, 97.7%)

90.6%

(81.3%, 95.4%)

90.6%

(81.3%, 95.4%)

93.3%

(84.8%, 97.2%)

Premenopausal

92.6%

(88.4%, 95.4%)

95.2%

(91.5%, 97.3%)

97.8%

(94.9%, 99.1%)

89.6%

(86.3%, 92.1%)

92.6%

(89.8%, 94.7%)

94.7%

(92.2%, 96.5%)

89.0%

(84.1%, 92.5%)

92.7%

(88.3%, 95.5%)

97.0%

(93.4%, 98.7%)

84.4%

(78.3%, 88.9%)

89.9%

(84.5%, 93.4%)

94.0%

(89.3%, 96.6%)

Postmenopausal

90.7%

(84.5%, 94.5%)

93.8%

(88.3%, 96.7%)

95.7%

(90.6%, 98.0%)

91.1%

(87.1%, 93.9%)

93.2%

(89.5%, 95.6%)

94.2%

(90.7%, 96.4%)

88.8%

(82.3%, 93.0%)

89.5%

(83.2%, 93.5%)

96.4%

(91.5%, 98.5%)

91.9%

(86.4%, 95.2%)

92.5%

(87.2%, 95.7%)

94.4%

(89.5%, 97.0%)

ypT0

91.7%

(87.8%, 94.4%)

94.7%

(91.3%, 96.8%)

97.2%

(94.4%, 98.6%)

91.1%

(88.6%, 93.1%)

93.2%

(91.0%, 94.9%)

95.0%

(93.0%, 96.4%)

91.0%

(87.0%, 93.9%)

92.7%

(88.9%, 95.2%)

96.6%

(93.5%, 98.2%)

90.6%

(86.4%, 93.5%)

92.1%

(88.1%, 94.8%)

94.6%

(91.1%, 96.8%)

ypTis

92.4%

(84.7%, 96.3%)

94.6%

(87.5%, 97.7%)

96.7%

(90.0%, 98.9%)

83.8%

(74.2%, 90.1%)

90.6%

(82.1%, 95.2%)

91.6%

(83.0%, 95.9%)

82.0%

(71.9%, 88.8%)

87.0%

(77.8%, 92.6%)

97.4%

(90.1%, 99.4%)

79.7%

(69.2%, 86.9%)

88.2%

(79.1%, 93.5%)

93.1%

(85.4%, 96.9%)

  1. BMI body mass index, DDFS distant disease-free survival, DFS disease-free survival, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, HR hormone receptor, OS overall survival, TNBC triple-negative breast cancer
Back to article page